Definitive Contract HHSN261201500073C

This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...

This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Radiopharmaceutical Imaging and Dosimetry, LLC, doing business as Radiopharmaceutical Imaging & Dosimetry LLC, a small business. The contract, valued at $299,275, is for a Small Business Innovation Research (SBIR) Phase I project to optimize targeted radionuclide therapy for metastatic liver cancer patients. This contract supports the NCI's broader...

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services' National Institutes of Health, to Radiomedix, Inc., a small disadvantaged business. The contract, valued at $1,994,002.00, is for the development of targeted radionuclide therapy using 212Pb-octreotate analogs for the treatment of neuroendocrine tumors. The contract was awarded on September 18, 2018 and has a completion date of...

This is a $300,000.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Icagen, Inc. for a Small Business Innovation Research (SBIR) Phase I project titled "SYSTEMIC TARGETED RADIONUCLIDE THERAPY FOR CANCER TREATMENT". The period of performance is from September 22, 2015 to June 21, 2016, with an ultimate completion date of September 30, 2016. This contract was not set aside for a specific business size or type. The goal of this SBIR...

This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Neuralrad LLC, a small business, for $454,559.00. The contract was awarded under the SBIR (Small Business Innovation Research) program to support the development of "Quantitative Imaging Software Tools for Cancer Diagnosis and Treatment Planning" as described in the original solicitation. This Phase I SBIR contract has a period of performance from...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...

This is a $398,604.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded to Infotech Soft, Inc. (a woman-owned for-profit organization) by the National Cancer Institute. The contract is for the development of quantitative imaging software tools to assist with cancer diagnosis and treatment planning. The contract is a definitive, firm fixed-price agreement, indicating a well-defined scope of work. This SBIR award is part of the National Cancer Institute's efforts to...

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

<p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. government. The contract, valued at $1,499,398.79, was awarded to Siamab Therapeutics, Inc. to develop novel therapeutic agents that target cancer stem cells, as described in SBIR Topic 326. The contract has a period of performance through September 18, 2018 and is a Cost Plus Fixed Fee definitive contract.</p>